title: HLA antigens and complement C4 allotypes in patients with chronic biologically false positive (CBFP) seroreactions for syphilis: a follow-up study of SLE patients and CBFP reactors.
abstract: We report a follow-up of our previous study of HLA markers in 118 unrelated patients: 49 with definite systemic lupus erythematosus (SLE) (group 1), 32 with definite or probable SLE and chronic biologically false positive (CBFP) seroreactions for syphilis (group 2), and 37 CBFP reactors (group 3). Definite SLE was confirmed in 28 (90.3%) of the patients in group 2, equally in HLA B8- and HLA B7-positive patients. Three of the CBFP reactors developed SLE, two (40%) out of five HLA B8-positive as compared to one (6.6%) out of 15 HLA B7-positive CBFP reactors (P = 0.07). Fourteen patients died (groups 1 and 2). Eight of the 24 HLA B8-positive patients died in contrast to one of the 20 HLA B7-positive patients (P < 0.02). Of the CBFP reactors, 70.9% had complement C4 null alleles as compared to 47.9% in controls (P = 0.05) and 50% had C4A null alleles as compared to 17.8% in controls (P < 0.05). C4B null alleles were found in 28.6% (28.6% in controls, P is not significant). The null alleles for C4A were not solely in a linkage disequilibrium with the HLA B8 DR3 haplotype. CBFP reactors with C4A null alleles had a higher risk of developing SLE, lupus-like disease or symptoms such as photosensitivity, cutaneous vasculitis and/or autoantibodies than did those with no C4A null alleles (P < 0.02).
authors.affiliation: Department of Dermatology, Karolinska Institute, Stockholm, Sweden.
authors.forename: E A
authors.initials: EA
authors.lastname: Stephansson
authors.forename: S
authors.initials: S
authors.lastname: Koskimies
authors.forename: M L
authors.initials: ML
authors.lastname: Lokki
mesh_terms: D000293:Adolescent; D000328:Adult; D000483:Alleles; D002648:Child; D015934:Complement C4a / Q000032:analysis / Q000235:genetics / Q000276:immunology*; D004797:Enzyme-Linked Immunosorbent Assay; D005189:False Positive Reactions; D005260:Female; D005455:Fluorescent Antibody Technique; D005500:Follow-Up Studies; D006680:HLA Antigens / Q000032:analysis / Q000235:genetics / Q000276:immunology*; D015793:HLA-B7 Antigen / Q000032:analysis / Q000235:genetics / Q000276:immunology; D015795:HLA-B8 Antigen / Q000032:analysis / Q000235:genetics / Q000276:immunology; D006239:Haplotypes; D006801:Humans; D005779:Immunodiffusion; D007126:Immunoglobulin Allotypes / Q000032:analysis / Q000235:genetics / Q000276:immunology*; D008180:Lupus Erythematosus, Systemic / Q000175:diagnosis / Q000453:epidemiology / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012307:Risk Factors; D013587:Syphilis / Q000453:epidemiology / Q000276:immunology*; D013588:Syphilis Serodiagnosis / Q000592:standards*
chemical_list: D006680:HLA Antigens; D015793:HLA-B7 Antigen; D015795:HLA-B8 Antigen; D007126:Immunoglobulin Allotypes; D015934:Complement C4a